Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of LY900014 Added to Insulin Treatment in Type 2 Diabetes
jRCT2080223610Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of insulin lispro in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Started Aug 2017; status: completed.
02
Drugs
insulin lispro
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080223610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223610.